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Although sitaﬂoxacin (STFX) is known to have a favorable
minimum inhibitory concentration for Mycobacterium avium,
few studies have evaluated the clinical efﬁcacy of an STFX-
containing regimen for pulmonary M avium complex (MAC)
disease. To evaluate the clinical efﬁcacy of STFX-containing reg-
imens for relapsed or refractory pulmonary MAC disease, we ret-
rospectively reviewed 18 patients with pulmonary MAC disease
who received STFX for at least 4 weeks for pulmonary MAC dis-
ease between January 2008 and February 2016. Of 18 patients, 10
(55.6%) showed improved radiological characteristics and 8
(44.4%) showed negative sputum cultures at 6 months. Regarding
the clinical symptoms, improvements were observed in decreas-
ing order in sputum production (77.8%), cough (72.2%), and
malaise (55.6%). Common adverse events included nausea or
vomiting (38.9%), followed by loose stool or diarrhea (27.8%)
and sleepiness (11.1%). Although this study contained a small
number of subjects, we describe a STFX-containing regimen
that was effective in achieving sputum culture negative conver-
sions and had an acceptable adverse events proﬁle.
Keywords. ﬂuoroquinolone;Mycobacterium avium complex;
nontuberculous mycobacteria; salvage therapy; sitaﬂoxacin.
Pulmonary Mycobacterium avium complex (MAC) disease is
becoming more prevalent worldwide [1]. This disease causes
progressive deterioration of lung function and possible chronic
respiratory failure. Although physicians have wrestled with this
disease for a long time, pulmonary MAC disease is refractory in
nature and often difﬁcult to control under clinical conditions.
According to the 2007 American Thoracic Society/Infectious
Disease Society of America (ATS/IDSA) guideline, the standard
treatment regimen for pulmonary MAC disease contains a com-
bination of rifampicin (RFP), ethambutol (EB), and macrolides
(clarithromycin [CAM] or azithromycin) [2]. Macrolides are
the key drug for treatment of MAC disease, and macrolide-
containing therapy can eradicate MAC strains in 50%–60% of
cases as an initial therapy [2]. However, it is known that micro-
biological recurrence is relatively common after successful treat-
ment [3, 4]. Because many of these cases are refractory to
standard therapy, current treatment regimens for pulmonary
MAC disease remain unsatisfactory in these cases. In recent stud-
ies, certain ﬂuoroquinolones have been receiving attention as al-
ternative drugs for the therapy of pulmonary MAC disease. Koh
et al [5] reported the advantages of moxiﬂoxacin (MFLX)-
containing treatments in refractory pulmonary MAC disease.
Fujita et al [6] conducted a randomized control trial comparing
gatiﬂoxacin (GFLX)-containing regimens and CAM-containing
regimens, and showed the noninferiority of GFLX. Sitaﬂoxacin
([STFX] Gracevit) is a ﬂuoroquinolone oral antibiotic that inhib-
its deoxyribonucleic acid replication in bacteria. It was released in
June 2008 and is currently marketed in Japan and Thailand. Sita-
ﬂoxacin is known to have similar minimum inhibitory concen-
tration in vitro and in vivo for M avium when compared with
other commercially available quinolones that show the clinical ef-
ﬁcacy for pulmonary MAC disease [7]. However, there is limited
experience regarding the use of STFX in the treatment of pulmo-
nary MAC disease [8]. Therefore, we conducted a retrospective
study to analyze the clinical efﬁcacy of STFX-containing regi-
mens among several teaching hospitals in Japan.
PATIENTS AND METHODS
Study Design and Participants
This was a multicenter retrospective study conducted among 3
teaching hospitals in Japan: National Hospital Organization
Kyoto Medical Center (600 beds, Kyoto), Kyoto University
Hospital (1121 beds, Kyoto), and Fukuoka University Hospital
(915 beds, Fukuoka). To evaluate the clinical efﬁcacy and side
effects of STFX-containing regimens, we retrospectively re-
viewed 18 patients with pulmonary MAC disease who received
STFX for at least 4 weeks for pulmonary MAC disease between
January 2008 and February 2016. All patients met the 2007
ATS/IDSA diagnostic criteria and tested negative for human
immunodeﬁciency virus infection. Patients were either refrac-
tory for a standard therapy or relapse after a standard therapy.
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We considered standard therapy as receiving a combination of
macrolide and RFP- or EB-containing regimen. We deﬁned re-
fractory status as presenting continuous positive sputum culture
after at least 1 year of standard therapy. The local institutional
review boards approved this retrospective study.
Clinical Evaluation
We evaluated treatment response by the negative conversion of
sputum culture, radiographic changes of computed tomography
(CT) scan data, and clinical symptoms. The negative conversion
of expectorated sputum culture was deﬁned as 3 consecutive neg-
ative sputum cultures. If sputum was not expectorated, the sputum
was considered to have converted to negative [6]. Radiographic
changes of CT scan data and clinical symptoms were evaluated
as improved, unchanged, or worse at 3 months and 6 months
after STFX-containing treatment was started [6, 9].All radiograph-
ic reports were reviewed by 1 andmore board certiﬁed radiologists.
In accordance with previous reports, we deﬁned radiological clas-
siﬁcation as 3 forms; nodular bronchiectatic (NB) form, ﬁbrocavi-
tary (FC) form, and NB + FC form [10, 11]. Although we did not
evaluate dose ranges, we gave STFX between 50 mg and 100 mg
ranges according to previous report [12]. Type, frequency, and se-
verity of adverse events were also recorded during the course of
treatment with STFX. Severity of adverse events were evaluated ac-
cording to Common Terminology Criteria for Adverse Events
(CTCAE), version 4.0. We extracted all data from the electronic
medical records in participants’ institutions.
RESULTS
We reviewed 18 patients from participating hospitals. Charac-
teristics of participants are shown in Table 1. Participants
were aged 66.6 ± 7.5 years and predominantly infected with
Mycobacterium intracellulare. Two patients had coinfection
with Pseudomonas aeruginosa. Sitaﬂoxacin was used because
of relapse in 4 patients and refractory state in 14 patients. All
patients had received prior treatment for pulmonary MAC dis-
ease; 13 (72.2%) and 5 (27.8%) had received 1 and 2 or more
regimens, respectively, before starting the STFX-containing reg-
imen. Clarithromycin, RFP, and EB were frequently used as
companion drugs with STFX. Two patients also received strep-
tomycin twice a week. The median duration of STFX adminis-
tration was 12.1 ± 7.3 months. The starting dose of STFX was
100 mg/day for 17 patients and 50 mg/day for 1 patient. Of
the 17 patients receiving 100 mg/day STFX, 2 required reduc-
tion to 50 mg/day in the course of therapy. Radiological ﬁnd-
ings were classiﬁed into 3 forms; there were 8 patients with
the NB form, 4 with the FC form, and 6 with the NB + FC form.
Treatment responses are shown in Table 2. Of 18 patients, 6
(33.3%) and 8 (44.4%) improved their sputum culture status at 3
months and 6 months after therapy, respectively. Eight patients
(44.4%) achieved negative conversion of their sputum culture at
6 months. Regarding the clinical symptoms, improvements
were seen in sputum production (77.8%), followed by cough
(72.2%) and malaise (55.6%), at 6 months. No clinical symp-
toms changed to worse during STFX treatment.
Regarding the radiological ﬁndings, 6 of 8 patients (75.0%) with
the NB form showed improvements in the abnormal shadows. By
contrast, only 1 of 4 patients (25.0%) with the FC form improved.
Type, frequency, and severity of adverse events observed in
this study are shown in Table 3. Gastrointestinal symptoms
were most commonly observed as adverse events; of these, nau-
sea was the most frequent. Two patients required dose reduction
of STFX because of nausea and diarrhea, and 2 patients ﬁnally
discontinued the STFX-containing regimen because of diarrhea
and bitterness of the drug. Serious adverse events with grade 3
or more were not observed during STFX administration.
DISCUSSION
Controversy remains regarding the clinical beneﬁts of ﬂuoro-
quinolone-containing regimens in the treatment of pulmonary
Table 1. Characteristic of Participants With Relapsed or Refractory
Pulmonary Mycobacterium avium Complex Diseasea
Characteristics n = 18
Age, years 66.6 ± 7.5
Gender (female) 15 (83.3)
Body mass index, kg/m2 18.7 ± 2.8
Infected MAC strain (Mycobacterium intracellulare) 11 (61.1)
Coinfected microorganism
Pseudomonas aeruginosa 2 (11.1)




Autoimmune disease 3 (16.3)
Use of corticosteroids 1 (5.6)
Radiographic pattern
Nodular bronchiectatic form 8 (44.4)
Fibrocavitary form 4 (22.2)
NB + FC form 6 (33.3)
History of previous treatment
One regimen 13 (72.2)
Two or more regimens 5 (27.8)










Fluoroquinolone (other than STFX) 3 (16.7)
Abbreviations: COPD, chronic obstructive pulmonary disease; FC, fibrocavitary;
MAC, Mycobacterium avium complex; NB, nodular bronchiectatic; SD, standard deviation;
STFX, sitafloxacin.
a Data show either number (%) of patients or mean ± SD.
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MAC disease. Although ciproﬂoxacin-containing regimens failed
to show any advantages [13],MFLX-containing regimens showed
a certain level of efﬁcacy in the treatment of refractory pulmonary
MAC disease [5]. Both STFX and MFLX displayed favorable in
vitro and in vivo activities against M avium strains [7]; however,
STFX exhibited slightly greater therapeutic efﬁcacy than MFLX
based on intrapulmonary bacterial elimination [7]. Although
the present preliminary study included only a small number of
subjects, the results revealed that use of STFX-containing regi-
mens in the treatment of pulmonary MAC disease was clinically
effective and acceptable to patients. Eight of 18 patients (44.4%)
in our preliminary study achieved negative conversion of sputum
culture at 6 months. This therapeutic efﬁcacy compared favorably
with MFLX-containing regimens. Radiological ﬁndings were
improved in 10 of 18 patients (55.6%) at 6 months; however,
response to STFX-containing regimens tended to be smaller in
patients with the FC than NB form. This observation might be
related to the fact that FC disease is known as a factor causing
refractory disease with poor prognosis [10, 14]. Fluoroquinolones
may cause many adverse events, and long-term use is potentially
of concern. Previous studies found that adverse events mani-
festing as gastrointestinal symptoms were more frequently
observed with STFX-containing regimens than MFLX- or
GFLX-containing regimens [5, 6]. Our study ﬁndings agreed
with those results in that gastrointestinal symptoms were the
main adverse events that might have hindered prolonged use of
ﬂuoroquinolones. However, all but 1 patient could tolerate the
gastrointestinal symptoms, and we did not experience serious ad-
verse events such as severe arrhythmia or seizures during STFX
administration.
This study has several limitations. First, the study had a ret-
rospective design and included only a small number of patients.
Although our multicenter study could reduce the recruitment
bias, the results should not be overemphasized. Second, because
we did not examine the drug susceptibility of STFX or CAM in
this study, we could not discuss the relationship between clinical
efﬁcacy and drug susceptibility. Furthermore, the assessment
tools of clinical efﬁcacy of STFX were not objective. Third, con-
cerns relating to drug resistance with combination therapy are
not addressed in this study. Grifﬁth et al [15] warned that com-
bination therapy with CAM and levoﬂoxacin could induce
CAM-resistant MAC. Furthermore, because pulmonary MAC
patients are known to have possible coinfection with other mi-
croorganisms, especially P aeruginosa [16], long-term use of
ﬂuoroquinolones may induce drug resistance in microorgan-
isms other than MAC. Finally, the follow-up periods of STFX
administration in this study were less than those of convention-
al standard therapy. These shorter follow-up periods might have
led to overestimation of the effectiveness of STFX because in-
stances of later recurrence and adverse events of STFX treat-
ment might have been missed. To overcome and clarify these
limitations, prospective study is warranted.
Table 2. Response to Treatment With Sitafloxacin-Containing Regimena
Parameters
3 Months After Therapy 6 Months After Therapy
Worse Unchanged Improved Worse Unchanged Improved
Clinical symptoms (n = 18)
Cough 0 8 (44.4) 10 (55.6) 0 5 (27.8) 13 (72.2)
Sputum 1 (5.6) 5 (27.8) 12 (66.7) 0 4 (22.2) 14 (77.8)
Hemosputum 0 13 (72.2) 5 (27.8) 0 12 (66.7) 6 (33.3)
Fever 0 15 (83.3) 3 (16.7) 0 15 (83.3) 3 (16.7)
Malaise 0 13 (72.2) 5 (27.8) 0 8 (44.4) 10 (55.6)
Sputum culture status (n = 18) 1 (5.6) 11 (61.1) 6 (33.3) 0 10 (55.6) 8 (44.4)
Radiological findings (n = 18)
Nodular bronchiectatic form (n = 8) 0 4 (50.0) 4 (50.0) 0 2 (25.0) 6 (75.0)
Fibrocavitary form (n = 4) 0 2 (50.0) 2 (50.0) 1 (25.0) 2 (50.0) 1 (25.0)
NB + FC form (n = 6) 0 4 (66.7) 2 (33.3) 0 3 (50.0) 3 (50.0)
Abbreviations: FC, fibrocavitary; NB, nodular bronchiectatic.
a Data show number (%) of patients.
Table 3. Type, Frequency, and Severity of Adverse Events Observed
During Sitafloxacin Administrationa
Type of Adverse Event Total Number Grade 1 Grade 2
Grade 3
or More
Nausea 6 5 (83.3) 1 (16.7) 0
Loose stool 3 3 (100) 0 0
Diarrhea 2 1 (50.0) 1 (50.0) 0
Sleepiness 2 1 (50.0) 1 (50.0) 0
Vomiting 1 1 (100) 0 0
Bitterness of drug 1 1 (100) 0 0
ECG changesb 1 1 (100) 0 0
Elevation of liver enzymes 1 0 1 (100) 0
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; ECG,
electrocardiogram.
a Data show number (%) of patients. Grade of adverse event was evaluated according to
CTCAE, version 4.0.
b ECG change of transient QT prolongation was detected in a patient.
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CONCLUSIONS
In conclusion, STFX may be effective and acceptable as a sal-
vage therapy for relapsed or refractory pulmonaryMAC disease.
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